



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dmc-rc@esic.nic.in

U-25/12/Exemption under Public Procurement (MII)Order/2022 -MedV(E-101005) दिनांक: 13.11.2024

1523

सेवामें,

**Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States**

ADDENDUM – DG ESIC RC 156/76

विषय: **Purchase of drugs & Dressings under DG ESIC Rate Contract 156.**

संदर्भ: No. U-25/12/DG ESIC/RC /156/2023-Med V for RC 156, Date-10.06.2024.

महोदय/महोदया,

This is in reference to the Rate Contract no 156, valid upto 09/06/2026, the following item is included:-

Item No.	Item Name and Description	Brand name if any	Packing	Name of the Firm	Firm Rate per unit (in Figures)	Firm Rate per unit (in Words)	Preference	Description of stores accepted
2131	Ruxolitinib Tab/Cap-Each Tab/Cap Contains Ruxolitinib 5mg	Jakavi	6x10 Tablets	Novartis Healthcare Private Limited	1487.90	Rupees One Thousand Four Hundred Eighty Seven and Ninety Paise only	L1 and Only	Same as in the item

All terms & conditions of the DGESIC RC 156 will be applicable.

This issues with the approval of Director General.

C. Khakha

Medical Commissioner (Procurement)

डॉ. सेसिल क्रिस्टोफर खाखा / Dr. Cecil Christopher Khakha
विक्रित्ता आयुक्त (प्रोक्वोरमेंट) / Medical Commissioner (Procurement)

क.रा.बी.नि. (मु.) / E.S.I.C. (H.Q.)

श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02
Panchdeep Bhawan, CIG Marg, New Delhi-02

Copy for information to:-

1. PPS/PS to DG/FC/MC.
2. WCM for uploading on ESIC website
3. M/s Novartis Healthcare Private Limited 3rd Floor, Vatika Business Center, Thapar House, Gate No.1, 124, Janpath Road, Janpath, New Delhi-110001 (email- orders.imindia@novartis.com, vikas.ranjan@novartis.com) for information please.
4. Guard file / Spare copy.
5. Hindi cell for translation.

Medical Commissioner (Procurement)

U-25/12/154-158/Amendment/Price/2024



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in ☎ 011-23604773, 23604774, 23604775, 23604776, 23604777, 23604778, 23604779, 23604780, 23604781, 23604782, 23604783, 23604784, 23604785, 23604786, 23604787, 23604788, 23604789, 23604790, 23604791, 23604792, 23604793, 23604794, 23604795, 23604796, 23604797, 23604798, 23604799, 23604800, 23604801, 23604802, 23604803, 23604804, 23604805, 23604806, 23604807, 23604808, 23604809, 23604810, 23604811, 23604812, 23604813, 23604814, 23604815, 23604816, 23604817, 23604818, 23604819, 23604820, 23604821, 23604822, 23604823, 23604824, 23604825, 23604826, 23604827, 23604828, 23604829, 23604830, 23604831, 23604832, 23604833, 23604834, 23604835, 23604836, 23604837, 23604838, 23604839, 23604840, 23604841, 23604842, 23604843, 23604844, 23604845, 23604846, 23604847, 23604848, 23604849, 23604850, 23604851, 23604852, 23604853, 23604854, 23604855, 23604856, 23604857, 23604858, 23604859, 23604860, 23604861, 23604862, 23604863, 23604864, 23604865, 23604866, 23604867, 23604868, 23604869, 23604870, 23604871, 23604872, 23604873, 23604874, 23604875, 23604876, 23604877, 23604878, 23604879, 23604880, 23604881, 23604882, 23604883, 23604884, 23604885, 23604886, 23604887, 23604888, 23604889, 23604890, 23604891, 23604892, 23604893, 23604894, 23604895, 23604896, 23604897, 23604898, 23604899, 23604900, 23604901, 23604902, 23604903, 23604904, 23604905, 23604906, 23604907, 23604908, 23604909, 23604910, 23604911, 23604912, 23604913, 23604914, 23604915, 23604916, 23604917, 23604918, 23604919, 23604920, 23604921, 23604922, 23604923, 23604924, 23604925, 23604926, 23604927, 23604928, 23604929, 23604930, 23604931, 23604932, 23604933, 23604934, 23604935, 23604936, 23604937, 23604938, 23604939, 23604940, 23604941, 23604942, 23604943, 23604944, 23604945, 23604946, 23604947, 23604948, 23604949, 23604950, 23604951, 23604952, 23604953, 23604954, 23604955, 23604956, 23604957, 23604958, 23604959, 23604960, 23604961, 23604962, 23604963, 23604964, 23604965, 23604966, 23604967, 23604968, 23604969, 23604970, 23604971, 23604972, 23604973, 23604974, 23604975, 23604976, 23604977, 23604978, 23604979, 23604980, 23604981, 23604982, 23604983, 23604984, 23604985, 23604986, 23604987, 23604988, 23604989, 23604990, 23604991, 23604992, 23604993, 23604994, 23604995, 23604996, 23604997, 23604998, 23604999, 23605000

U-25/12/154-158/Amendment/Price/2024(E:887520) | 292

Dated: 08.08 2024

To

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment - 69 in DGESIC RC 156 (E:887520)

Sub: Rate Revision under DGESIC Rate Contract 156-reg.

Ref No. U-25/12/DG-ESIC/RC/156/2023-MedV(E101005) dated 10th June.2024 effective from 10.06.2024 to 09.06.2026.

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name	RC No. Item No. Pref. in RC	Existing Price in DG ESIC RC-144C	Amended reduced Price w.e.f 30th July, 2024	Change in Pref.	Recovery / Difference of rates (If any)
M/s Novartis Healthcare Private Limited	Ruxolitinib Tab/Cap- Each Tab/Cap to contains Ruxolitinib 15 mg. JAKAVI	156 2129 L-1 and ONLY	Rs. 2,981.20	Rs. 2,951.39	No change	Difference in rates to be deducted for supply orders placed wef 30th July 2024, (if any)

- The said amendment has been issued on the request of the firm M/s. Novartis Healthcare Private Limited.
- The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per Drug & Cosmetic Act.
- All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and to maintain records of the same.
- Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority / DDOs of the respective institution.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

शुभेच्छु

Signed by Anita Karanwal
Date: 12-08-2024 09:51:22
उप चिकित्सा आयुक्त (दर सौदा)

Copy for information to:

- M/s. Novartis Healthcare Private Limited, 3rd Floor, Vatika Business Centre, Thapar House, Gate no. 1, 124, Janpath Road, Janpath, New Delhi-110001. (Email: orders.imindia@novartis.com vijay-l.mehta@novartis.com)
- Website Content Manager with request for uploading on ESIC website.



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dms.ec@esic.nic.in

U-25/12/154-158/Amendment/Packing/2024-MedV (E:869597) /358

To

Director (Medical) Delhi/Director (Medical) NOIDA

Dean, All ESIC PGIMSR's, Medical & Dental Colleges

Medical Superintendents-All ESIC Hospitals

Director IMS, ESI Scheme-All States

Amendment -74 / DGESIC RC 157

Sub: Revision in Pack size of an approved item no.2352 in DGESIC RC 157 - Tab. Secnidazole from existing Strip of 1x10 tab to Strip of 1x2 tab of M/s Unicare India Ltd.-reg.

Ref: No. U-25/12/DG-ESIC/RC/157/2023-Med.V(101005) for DGESIC RC 157 valid w.e.f. 10.06.2024 to 09.06.2023

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name	RC No./Item No./ Pref. in RC	Existing Firm Pack Size in DGESIC RC 157	Amended Firm Pack Size in DGESIC RC 157	Change in Price (if any)
M/s Unicare India Ltd	Secnidazole Tab/Cap - Each Tab/Cap to contain: Secnidazole 1 gm	157 2352 L-1 and ONLY	Strip of 10 tabs	Strip of 2 tabs	No change in Price Rs.13.25 per tab

1. The said amendment has been issued on the request of firm M/s Unicare India Ltd.
2. The drug supplied by M/s Unicare India Ltd. shall continue to adhere to composition, strength, etc as approved under the respective DGESIC Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act and any amendments thereof.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

शुभेच्छु

Signed by Neeta Garbiyal
Date: 09-10-2024 15:04:53
उप-चिकित्सा आयुक्त (दर संविदा)

Copy for information to:

1. M/s Unicare India Ltd , C-21, 22 & 23, Sector-3, Noida-201301 (Email:unicare@unicareindia.com).
2. Website Content Manager with request for uploading on ESIC website.



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dmc-rc@esic.nic.in

U-25/12/149-153/Amendment/FirmName/2023-Med.V (E:185404)/570 Dated: 13-12-2024
16

सेवा में,

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment – 82

DG ESIC RC No. 149, 151 & 156

Sub: Amendment for e-mail ID in respect of M/s. Zydus Lifesciences Limited in DG ESIC RC No. 149, 151 & 156-reg.

Ref.: U-25/12/149-153/2021-MedV dated 21.10.2022 valid upto 31.10.2024, extended up to 30.04.2025 and U-25/12/DG-ESIC/RC/156/2023-MedV(E-101005) dt. 10.06.2024 valid upto 09.06.2026.

Sir/Madam,

Reference captioned subject and on the request of **M/s. Zydus Lifesciences Limited**, following amendment/update may please be noted:

Firm Name	RC No.	Existing e-mail ID in DGESIC RC	Amended E-mail ID in DGESIC RC
M/s. Zydus Lifesciences Limited	149, 151 & 156	email Id: NishuS.Dubey@zyduslife.com Namit.gaur@zyduslife.com	email: zll_institution_business@zyduslife.com

यह पत्र चिकित्सा आयुक्त (पी.सी), कर्मचारी राज्य बीमा निगम के अनुमोदन से जारी किया जाता है।

Signed by Neeta Garbiyal
Date: 13-12-2024 17:48:04

उप चिकित्सा आयुक्त (दर संविदा)

Copy for information to:-

1. M/s Zydus Lifesciences Limited, Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Ahmedabad-382481, Gujarat (zll_institution_business@zyduslife .com , NishuS.Dubey@zyduslife.com)
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dmrc@esic.nic.in

U-25/12/142C-146C/Amendment/Site/2022-MedV (e-85591)

To

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

(संशोधन / Amendment -86)

Sub: Amendment in Change in Manufacturing Site address of M/s. Eli Lilly Company (India) Pvt. Ltd., for the product Item no. 1691 in RC-145C and Item no.1770 in RC-157 -reg

Ref.: U-25/12/142C-146C/2019-Med.V (RC-145C) dt. 14.10.2021, extended upto 30.04.2025
U-25/12/ExemptionunderPublicProcurement(MII)Order/2022-Med.V(E-101005) Dt: 10.06.2024
effective w.e.f. 10.06.2024 to 09.06.2026

Sir/Madam,

The following amendment may please be noted:

RC No	Item No.	Item Name	Existing Mfg. Site	New Manufacturing Site Amendment
145C	1691	Insulin Inj.- Each cartridge to contain: 25% Lispro and 75% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin] 3ml Cartridge (Brand: Humalog Mix 25)	M/s Eli Lilly Italia S.P.A., Via Gramsci 731-733, Sesto Fiorentino - Firenze, Italy 50019	M/s. Lilly France SAS, Centre de Production 2, Rue Du Colonel Lilly, Zone Industrielle, F-67640 Fegersheim, France
157	1770	Insulin Lispro Inj.- Each Cartridge contain: Insulin Lispro (100IU/ml), [Monocomponent Insulin, recombinant DNA Origin] 3ml Cartridge (Brand Name: Humalog).		

1. The said amendment has been issued on the request of the firm **M/s. Eli Lilly Company (India) Pvt. Ltd.**

-2-

2. The drug(s) supplies by M/s. Eli Lilly Company (India) Pvt. Ltd. shall continue to adhere to composition, strength, standards and packing as approved under the respective DGESIC Rate Contract(s) & conform to the standards and specifications as per the Drug & Cosmetic Act and any amendments thereof.

3. M/s. Eli Lilly Company (India) Pvt. Ltd. shall continue to be governed by the Terms & Conditions of respective DGESIC Rate Contract(s).

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

Digitally signed by
Neeta Garbiyal
Date: 18-03-2025
14:07:53
एम. चिकित्सा आयुक्त (दर संविदा)

Copy for information to:

1. M/s. Eli Lilly Company (India) Pvt. Ltd. Plot no.92, Sector-32, Gurgaon-122001 Haryana (email: singh_inderpal@lilly.com)
2. Content Manager with request for uploading on ESIC website.
3. Guard file / Spare



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, 011-23604773, gmcr-rc@esic.nic.in

U-25/12/154-158/Amendment/Price/2024(E:887520) - 581

Dated: 18.12.2024
23

To

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment -81 in DGESIC RC 156

Sub: Rate Revision under DGESIC Rate Contract 156-reg.

Ref:U-25/12/DG-ESIC/RC/156/2023-MedV(E101005) dtd 10.06.2024 (RC valid wef 10.06.24 to 09.06.26).

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name/ Pack Size	RC No./ Item No./ Pref. in RC	Existing Price in DG ESIC RC- 156	Amended reduced Price w.e.f 26th Nov, 2024	Change in Pref.	Recovery / Difference of rates (If any)
M/s. AstraZeneca Pharma India Limited	Osimertinib Tab 80mg (Brand name: Tagrisso 80mg) 30 tabs (Strip of 10'sx3)	156 2456	Rs. 9,262.70 per tab	Rs.9,043.8367 per tab	No change	Difference in rates to be deducted for supply orders placed wef 26th Nov 2024
		L-1 and ONLY	Rs.2,77,881.00 per 30 tabs.	Rs.2,71,315.10 per 30 tabs.		

1. The said amendment has been issued on the request of the firm M/s. AstraZeneca Pharma India Limited.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per Drug & Cosmetic Act.
3. All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and to maintain records of the same.
4. Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority / DDOs of the respective institution.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

Signed by Neeta Garbiyal
Date: 18-12-2024 10:13:19

चिकित्सा आयुक्त (दर संविदा)

Copy for information to:

1. M/s. AstraZeneca Pharma India Limited, 12th Floor, N1, Manyata Embassy Business Park, Rachenahalli, Bangalore-560045.(institution.az@astrazeneca.com , rajiv.dutt@astrazeneca.com)
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy

U-25/12/154-158/Amendment/Price/2024



कर्मचारी राज्य बीमा निगम
(भारत एवं राज्यों में कार्य करने वाले)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.डी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.gov.in, 011-23604773, esic@govt.nic.in

U-25/12/154-158/Amendment/Price/2024(E:887520)

Dated:

To

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Regional Director/Director, ESI Scheme-All States

Amendment -80 in DGESIC RC 156 (E:887520)**Sub: Rate Revision under DGESIC Rate Contract 156-reg.**

Ref:U-25/12/DG-ESIC/RC/156/2023-MedV(E101005)dt.10.06.2024 effective from 10.06.2024 to 09.06.2026.
Addendum vide U-25/12/Exemption under Public Procurement(MIII) order/2022-MedV(E-101005)-523 dt.
13.11.2024 (Console no. 18800/2024 dt. 18.11.24)

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name	RC No. /Item No./ Pref. in RC	Existing Price in DG ESIC 156	Amended reduced Price w.e.f 13th Nov, 2024	Change in Pref.	Recovery / Difference of rates (if any)
M/s Novartis Healthcare Private Limited	Ruxolitinib Tab/Cap- Each Tab/Cap to contains Ruxolitinib 5 mg JAKAVI	156 2131 L-1 and ONLY	Rs.1,487.90	Rs.1,450.00	No change	Difference in rates to be deducted for supply orders placed w.e.f. 13th Nov 2024, (if any)

1. The said amendment has been issued on the request of the firm M/s. Novartis Healthcare Private Limited.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per Drug & Cosmetic Act.
3. All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and to maintain records of the same.
4. Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority / DDOs of the respective institution.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

शुभेच्छु

Signed by Neeta Garbiyal
Date: 29-11-2024 12:21:05

उप चिकित्सा आयुक्त (दर संविदा)

Copy for information to:

1. M/s. Novartis Healthcare Private Limited, 3rd Floor, vatika Business Centre, Thapar House , Gate no. 1, 124, Janpath Road, Janpath, New Delhi-110001.(Email: orders.imindia@novartis.com vijay-1.mehta@novartis.com)
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎:011-23604773, ✉:gms-rc@esic.nic.in

F.no. U-25/12/RC/Amendment/Dosage/Misc/2025-Med.V (E:1237671) / 72 Dt:Signed Date

सेवा में,

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

संशोधन/Amendment -05/2026

Sub:Amendment in Brand name for Item no.322 in DGESIC RC-155 and Item no. 2076 in DGESIC RC-160 in r/o M/s. Bajaj Healthcare Limited- reg

Ref:U-25/12/DG-ESIC/RC/155/2023-MedV(E-101005) effective from 10.06.24 to 09.06.26
:U-25/12/RC/159TO163/2022-MedV(E-117064) effective from 08.04.2025 to 07.04.2027

Sir/Madam,

कृपया निम्नलिखित संशोधन पर ध्यान दें:

The following amendment may please be noted:

RC No.	Item No.	Item Name	Approved Brand name	New Brand Name /Generic Name
155	322	Haemostatic Tab/cap- Each Tab/Cap to contain: Micronized Purified Flavonoid Fraction of Rutaceae 500mg Packing: 10 tablets Rate/Unit: Rs. 6.37 / Tab	DAFLOJAJ 500	VENOJAJ 500 (for Supply Orders till 31.03.2026). Thereafter, w.e.f. 01.04.2026, the Supplies will be in <u>GENERIC Name only</u>, without Brand Name (Same as in Item Name)
160	2076	Micronised- Purified Flavonoid Tab/Cap- Each Film coated Tab/Cap to contain: Micronized - Purified Flavonoid Fraction 1000mg-Composed of Diosmin 900mg (90%) And Flavonoids Expressed as Hesperidin	DAFLOJAJ 1000	The Supplies will be in <u>GENERIC Names only</u>, without Brand Name (Same as in Item Name)

	100mg(10%) Packing: 10 tablets Rate/Unit: Rs.11.77/Tab		
--	---	--	--

-2-

1. उक्त संशोधन M/s. Bajaj Healthcare Limited के अनुरोध पर जारी किया गया है।

The said amendment has been issued on the request of firm **M/s. Bajaj Healthcare Limited.**

2. M/s. Bajaj Healthcare Limited द्वारा आपूर्ति की जाने वाली दवा संबंधित डीजीईएसआईसी दर अनुबंध के तहत अनुमोदित संरचना, क्षमता आदि का पालन करती रहेगी और औषधि एवं सौंदर्य प्रसाधन अधिनियम और उसके किसी भी संशोधन के अनुसार मानकों और विशिष्टताओं के अनुरूप होगी।

The drug supplied by M/s. Bajaj Healthcare Limited shall continue to adhere to composition, strength, etc as approved under the respective DGESIC Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act and any amendments thereof.

3. सभी डीडीओ को सलाह दी जाती है कि यदि कोई जोखिम खरीद लागू हो, तो उसे फर्म द्वारा प्रस्तुत किए गए बाद के बिलों में विधिवत रूप से प्रभारित और वसूल किया जाना सुनिश्चित करें। ऐसी वसूलियों का उचित रिकॉर्ड भी रखा जाना चाहिए।

All DDOs are advised to ensure that any risk purchase, if applicable, is duly charged and recovered from the subsequent bills submitted by the firm. Proper records of such recoveries should also be maintained.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

Digitally signed by
Sanjiv Kochhar
Date: 10-03-2026
10:42:15

उप-चिकित्सा आयुक्त (दर संविदा)

Copy for information to:

1. Bajaj Healthcare Limited, 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39,
Road No. 23, Wagle Industrial Estate, Thane(W)-400604
Email:marketing@bajajhealth.com , shantaram@bajajhealthcare.com

2. Website Content Manager with request for uploading on ESIC website.



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आइ.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dmc-rc@esic.nic.in

U-25/12/154-158/Amendment/FirmName/2024-MedV(E-Comp:823452) /508 Web Upload
सेवा में,

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

शुद्धिपत्र/Corrigendum- 14 / 2025

Sub: Corrigendum in r/o Deletion of seven (07) items of M/s. Martin & Brown Biosciences in DGESIC RC 154,157 &158 -reg.

Ref:U-25/12/DG-ESIC/RC/154,157,158/2023-Med.V(E-101005) Dt: 10th June 2024, valid upto 09.06.2026.

Sir/Madam,

I am hereby directed to convey the approval of Competent Authority for deletion of following seven (07) drugs/items **awarded to M/s. Martin & Brown Biosciences** from the approved item list of DGESIC RCs-154, 157 & 158, as detailed below:

S. no.	RC No.	Item No.	Preference	Item Name/ Description
1	154	13	L1	Promethazine Symp - Each 5 ml to contain: Promethazine 5mg (Brand: PARAGEN)
2	157	196	L1 & Only	Chloroquine Symp - Each 5ml to contain: Chloroquine Phosphate 50mg (Brand: LAIRZO-AG)
3	157	1327	L1 & Only	Potassium Chloride Inj - Each ml to contain: Potassium Chloride I.P- 0.15gm (Brand: KALCO)
4	157	2397	L1 & Only	Methylegometrine Inj - Each ml to contain: Methylegometrine Inj.-0.2mg (Brand: METHATIN)
5	158	111	L1 & Only	Methyl Ergometrine Maleate Inj - Each ml to contain: Methyl Ergometrine Maleate 0.2mg (Brand:METHATIN)
6	158	2040	L1 & Only	Inj Calcium Gluconate - Each ml to contain: Calcium Gluconate 100mg (Brand: CALCY-MB)
7	157	1590b	L2*	Triamcinolone Inj - Each ml to contain: Triamcinolone 40mg (Brand: MBCORT-40)

S.no. 1-6 : Deletion of Complete Item - No Supply Orders to be placed to any firm for Item No. 13, 196, 1327, 2397, 111, 2040 in respective DG ESIC RC.

S.no. 7 : Deletion of firm M/s Martin & Brown Biosciences ONLY being L2. Supply Order can be placed to L1 firm for Item no. 1590b in DG ESIC RC-157 for continuity of supply.

This is for kind information and further necessary action.

यह पत्र सक्षम प्राधिकारी क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

Digitally signed by
Sanjiv Kochhar
Date: 29-09-2025

13:37:00
उप-चिकित्सक अधिकारी (दर संविदा)



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मह्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dmcr@esic.nic.in

U-25/12/154-158/Amendment/Packing/2024-Med.V (E:869597) /34

सेवा में,
Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

संशोधन (Amendment) -85/ DGESIC RC 156

विषय: Revision in Pack size of approved item no.1980 (Lenalidomide Tab/Cap 5mg) in DGESIC RC 156 from existing Pack of 10 to Strip of 7 of M/sBDR Pharmaceuticals International Pvt. Ltd-reg.

Ref: No. U-25/12/DG-ESIC/RC/156/2023-Med V(E-101005) , valid w.e.f. 10.6.2024 to 09.06.2026

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name	RC No. /Item No. /Pref. in RC	Existing Pack Size in DGESIC RC 156	Amended Pack Size in DGESIC RC 156
M/s. BDR Pharmaceuticals International Pvt. Ltd	Lenalidomide Tab/Cap- Each Tab/Cap to contain: Lenalidomide 5mg (GIOLEN)	156 1980 First and Only	Pack of 10 Capsule 1 x 10 (Rs.7.56 per 1 Tab / Cap)	Strip of 7 Capsule 1 x 7 (Rs. 7.56 per 1 Tab / Cap)

1. The said amendment has been issued on the request of the firm **M/s. BDR Pharmaceuticals International Pvt. Ltd.**

2. The drug supplied by M/s. BDR Pharmaceuticals International Pvt. Ltd shall continue to adhere to composition, strength, etc as approved under the respective DGESIC Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act and any amendments thereof.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

Digitally signed by
Neeta Garbiyal
Date: 19-03-2025
10:52:16 AM आयुक्त (दर संविदा)

Copy for information to:

1. M/s. BDR Pharmaceuticals International Pvt. Ltd., Administrative Office:3rd Floor, Engineering Centre, 9 Mathew Road, Opera House, Charni Road, Mumbai-400004 (Email:

manoj.kapoor@bdrpharma.com).

2. Website Content Manager with request for uploading on ESIC website.

3. Guard file / Spare copy